Insights from therapeutic trials : targeted therapies

Insights from therapeutic trials : targeted therapies
knowledge reported from many phase ii and that iii clinical trials evaluating
the role of egfr tki, erlotinib, and gefitinib, within the setting
of second and third line, nsclc claim for the next responsiveness
to these agents in ladies. within the iressa dose analysis in
advanced lung cancer ( ideal ) one and a pair of studies, gefitinib was
tested in patients with advanced nsclc previously treated with
one or 2 lines of chemotherapy, and female sex was associated
with improved outcomes. 138, 139 in the thoughtl a pair of study, 50% of
ladies had symptom improvements compared to 31% in men
and, additionally, 82% of partial responses occurred in women
( table 25. four ).
during a randomized double-blind, placebo-controlled phase
iii trial in second- and third-line advanced nsclc, 140 patients
treated with daily erlotinib had a response rate of eight. 9% with
a median survival of vi. seven months, leading to a 42% improvement
in median survival compared to patients receiving placebo
that had a median survival of four. seven months. one-year survival
rate was 31% within the erlotinib arm and 21% within the placebo arm.
response rate was statistically superior in ladies ( fourteen. 4% vs.
vi. 0% in men ) however within the multivariate analysis, sex didn't predict
increased response to erlotinib. during another massive randomized
study, a statistically significant higher response rate was observed
for gefitinib-treated ladies compared to men ( fourteen. 7% vs. five. 1%,
respectively ). this study included 1692 patients and failed to
demonstrate a survival improvement with gefitinib over placebo
in either overall population ( five. vi vs. five. one months ) or during adenocarcinomas
( vi. three vs. five. four months ).
in an oversized phase ii study, 138 patients with a diagnosis of
bronchoalveolar carcinoma were treated with gefitinib as firstor
second-line treatment. an exploratory subset analysis found
gefitinib a lot of active in ladies, and a statistically significant
distinction in survival was observed within the previously untreated
ladies versus men ( p zero. 04 ). 141
the improved survival observed in ladies treated with these
egfr tkis might be connected to differences in frequency of mutations
in tyrosine kinase domain of the egfr ( 20% in women
vs. 9% in men ), 142 a rised proportion of high egfr copy
range by fluorescence in situ hybridization ( fish ) or the next
egfr expression by immunohistochemistry.
within the ecog 4599 study, the benefit on survival of adding
bevacizumab to the doublet of carboplatin/paclitaxel was
consistently reported during all subgroups of patients ( measurable
vs. nonmeasurable disease, prior radiation therapy versus no
prior radiation therapy, prior weight loss of but 5% vs.
5% or a lot of, stage iiib with pleural effusion vs. stage iv ), but
not in ladies and within the elderly patient population. among
men, the median overall survival was eight. seven months within the standard
arm and 11. seven months within the experimental arm, whereas
in ladies, thirteen. one and thirteen. three months, respectively. this unexpected
increased survivorship of girls might be attributable
to imbalances between the 2 teams connected to graspn or
unknown baseline prognostic factors, to the use of second- and
third-line therapies might be connected to statistical likelihood or a
true sex-based distinction fourteen